SCHEMBL25787152

SCHEMBL25787152

CC(=O)N(CCCn1nnc(-c2ccccc2Nc2ccc(C(C)(F)P)cc2)n1)C(C)=O

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DDX3X O00571 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ MAPT P10636 1/20 0.39
▸ ABCG2 Q9UNQ0 7/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ HPGD P15428 2/20 0.38
▸ TSHR P16473 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ LMNA P02545 3/20 0.37
▸ ABCB1 P08183 2/20 0.37
▸ USP2 O75604 1/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ CNR2 P34972 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20553061 0.94 DDX3X (0.47) DDX3XSMN1; SMN2MAPTABCG2MEN1
SCHEMBL25786906 0.82 MAPT (0.47) SMN1; SMN2MAPTABCG2MEN1KMT2A
SCHEMBL25787163 0.81 KDM4E (0.52) SMN1; SMN2MAPTMEN1KMT2AHSD17B10
SCHEMBL25787116 0.81 DDX3X (0.40) DDX3XSMN1; SMN2MAPTABCG2MEN1
SCHEMBL21749296 0.81 DDX3X (0.43) DDX3XSMN1; SMN2MAPTABCG2ALDH1A1
SCHEMBL25787092 0.81 ABCG2 (0.45) DDX3XSMN1; SMN2MAPTABCG2KMT2A
SCHEMBL25787046 0.81 DDX3X (0.40) DDX3XSMN1; SMN2MAPTABCG2MEN1
SCHEMBL20551737 0.80 DDX3X (0.45) DDX3XSMN1; SMN2MAPTABCG2MEN1
SCHEMBL25787068 0.80 SMN1; SMN2 (0.40) DDX3XSMN1; SMN2MAPTABCG2MEN1
SCHEMBL20551702 0.80 DDX3X (0.49) DDX3XSMN1; SMN2MAPTABCG2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 DDX3X 1986/4885SMN1; SMN2 3035/4885MAPT 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback